WO1996002262A3 - Pharmaceutical compositions for the treatment of gastrointestinal distress comprising h2 receptor antagonists and antacids - Google Patents
Pharmaceutical compositions for the treatment of gastrointestinal distress comprising h2 receptor antagonists and antacids Download PDFInfo
- Publication number
- WO1996002262A3 WO1996002262A3 PCT/US1995/009004 US9509004W WO9602262A3 WO 1996002262 A3 WO1996002262 A3 WO 1996002262A3 US 9509004 W US9509004 W US 9509004W WO 9602262 A3 WO9602262 A3 WO 9602262A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- antacids
- pharmaceutical compositions
- receptor antagonists
- gastrointestinal distress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU31324/95A AU3132495A (en) | 1994-07-20 | 1995-07-18 | Pharmaceutical compositions for the treatment of gastrointestinal distress comprising h2 receptor antagonists and antacids |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27763294A | 1994-07-20 | 1994-07-20 | |
| US08/277,632 | 1994-07-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996002262A2 WO1996002262A2 (en) | 1996-02-01 |
| WO1996002262A3 true WO1996002262A3 (en) | 1997-02-13 |
Family
ID=23061722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/009004 Ceased WO1996002262A2 (en) | 1994-07-20 | 1995-07-18 | Pharmaceutical compositions for the treatment of gastrointestinal distress comprising h2 receptor antagonists and antacids |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU3132495A (en) |
| CO (1) | CO4410201A1 (en) |
| PE (1) | PE33896A1 (en) |
| WO (1) | WO1996002262A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112020350A (en) | 2018-04-27 | 2020-12-01 | 强生消费者公司 | Liquid oral pharmaceutical dosage form |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0492247A1 (en) * | 1990-12-21 | 1992-07-01 | Miles Inc. | Effervescent H2 blocker formulation |
| WO1992017164A1 (en) * | 1991-04-04 | 1992-10-15 | The Procter & Gamble Company | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress |
| WO1992017161A1 (en) * | 1991-04-04 | 1992-10-15 | The Procter & Gamble Company | Chewable antacid compositions |
| US5229137A (en) * | 1992-05-06 | 1993-07-20 | Brigham And Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
-
1995
- 1995-07-18 PE PE27413595A patent/PE33896A1/en not_active Application Discontinuation
- 1995-07-18 CO CO95031726A patent/CO4410201A1/en unknown
- 1995-07-18 AU AU31324/95A patent/AU3132495A/en not_active Abandoned
- 1995-07-18 WO PCT/US1995/009004 patent/WO1996002262A2/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0492247A1 (en) * | 1990-12-21 | 1992-07-01 | Miles Inc. | Effervescent H2 blocker formulation |
| WO1992017164A1 (en) * | 1991-04-04 | 1992-10-15 | The Procter & Gamble Company | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress |
| WO1992017161A1 (en) * | 1991-04-04 | 1992-10-15 | The Procter & Gamble Company | Chewable antacid compositions |
| US5229137A (en) * | 1992-05-06 | 1993-07-20 | Brigham And Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
Non-Patent Citations (1)
| Title |
|---|
| WASERSTEIN M ET AL: "IN-VIVO EVALUATION OF THE EFFECT OF ANTACIDS AND H-2 BLOCKERS ON INTRAGASTRIC PH IN THE GASTRIC AND DUODENAL ULCER", ACTA GASTROENTEROL LATINOAM, 15 (4). 1985 (RECD. 1986). 243-256. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996002262A2 (en) | 1996-02-01 |
| CO4410201A1 (en) | 1997-01-09 |
| PE33896A1 (en) | 1996-09-02 |
| AU3132495A (en) | 1996-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6076198A (en) | Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers | |
| WO2004021872A3 (en) | Tissue capturing devices | |
| NZ332117A (en) | Enteric-coated pharmaceutical compositions of mycophenolate | |
| WO2004035762A3 (en) | Microencapsulation and sustained release of biologically active polypeptides | |
| CA2262647A1 (en) | Methods for regulating gastrointestinal motility | |
| IE950632L (en) | Compositions and methods for treating gastrointestinal disorders | |
| CA2177209A1 (en) | Sacro-iliac joint mobilization device | |
| EP0614298A3 (en) | Bussystem protected against the uncoupling of earth connections. | |
| AU1030392A (en) | Compositions and methods for treating gastrointestinal disorders | |
| CA2131495A1 (en) | Double-layered oxcarbazepine tablets | |
| EP1431288A3 (en) | Electroluminescent iridium compounds with fluorinated phenylpyridines, phenylpyrimidines, and phenylquinolines and devices made with such compounds | |
| WO2001036487A3 (en) | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby | |
| DK0929234T3 (en) | Tablets containing a sweetener mixture | |
| CA2106215A1 (en) | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress | |
| WO1992018111A3 (en) | Pharmaceutical composition for the treatment of gastritis | |
| PT1140013E (en) | SUSPENSION TABLETS ANTIACIDS FOAM FORMERS | |
| WO1996002262A3 (en) | Pharmaceutical compositions for the treatment of gastrointestinal distress comprising h2 receptor antagonists and antacids | |
| AU2001295412A1 (en) | A novel polypeptide, a human cytokine receptor 10.67 and the polynucleotide encoding the polypeptide | |
| CY2167B1 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinylue benzimidazole and an anti-helicobacter agent f or the treatment of gastrointestinal disorders | |
| WO1994000113A3 (en) | Medicaments containing 5-ht4 receptor antagonists | |
| WO1999056769A3 (en) | Inhibition of helicobacter pylori proliferation | |
| AU8989391A (en) | Treatment of upset stomach associated with heartburn, sour stomach or acid indigestion with an effervescent h2 blocker formulation | |
| MY123805A (en) | Stabilized pharmaceutical composition based on quinupristine and dalfopristine and their preparation. | |
| ID20812A (en) | POLYOL COMPOUNDS, PRODUCTS AND USES | |
| EP2025754A3 (en) | Moraxella (Branhamella) catarrhalis antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LT LV MD MG MN MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG UZ |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LT LV MD MG MN MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG UZ |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 122 | Ep: pct application non-entry in european phase |